A detailed history of First Horizon Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 274,687 shares of GILD stock, worth $25.8 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
274,687
Previous 254,375 7.99%
Holding current value
$25.8 Million
Previous $17.5 Million 31.93%
% of portfolio
0.64%
Previous 0.53%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$66.59 - $83.99 $1.35 Million - $1.71 Million
20,312 Added 7.99%
274,687 $23 Million
Q2 2024

Jul 19, 2024

BUY
$63.15 - $72.88 $458,469 - $529,108
7,260 Added 2.94%
254,375 $17.5 Million
Q1 2024

Apr 26, 2024

BUY
$71.58 - $87.29 $181,526 - $221,367
2,536 Added 1.04%
247,115 $18.1 Million
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $214,607 - $243,370
-2,929 Reduced 1.18%
244,579 $19.8 Million
Q3 2023

Oct 27, 2023

BUY
$73.94 - $80.67 $158,527 - $172,956
2,144 Added 0.87%
247,508 $18.5 Million
Q2 2023

Aug 03, 2023

SELL
$76.01 - $86.7 $263,450 - $300,502
-3,466 Reduced 1.39%
245,364 $18.9 Million
Q1 2023

May 15, 2023

SELL
$77.31 - $88.08 $773,100 - $880,800
-10,000 Reduced 3.86%
248,830 $20.6 Million
Q4 2022

Feb 10, 2023

SELL
$62.32 - $89.47 $600,328 - $861,864
-9,633 Reduced 3.59%
258,830 $22.2 Million
Q3 2022

Nov 09, 2022

SELL
$59.54 - $68.01 $213,986 - $244,427
-3,594 Reduced 1.32%
268,463 $16.6 Million
Q2 2022

Aug 02, 2022

BUY
$57.72 - $65.01 $10.7 Million - $12 Million
184,741 Added 211.58%
272,057 $16.8 Million
Q1 2022

May 10, 2022

SELL
$57.92 - $72.58 $8.15 Million - $10.2 Million
-140,755 Reduced 61.72%
87,316 $5.19 Million
Q4 2021

Feb 09, 2022

BUY
$64.88 - $73.64 $333,029 - $377,994
5,133 Added 2.3%
228,071 $16.6 Million
Q3 2021

Nov 15, 2021

SELL
$67.69 - $73.03 $62.4 Million - $67.3 Million
-921,594 Reduced 80.52%
222,938 $15.6 Million
Q3 2021

Nov 09, 2021

BUY
$67.69 - $73.03 $63.8 Million - $68.8 Million
942,014 Added 465.15%
1,144,532 $79.9 Million
Q2 2021

Aug 09, 2021

BUY
$63.47 - $69.35 $824,665 - $901,064
12,993 Added 6.86%
202,518 $13.9 Million
Q1 2021

May 11, 2021

BUY
$60.0 - $68.46 $800,040 - $912,845
13,334 Added 7.57%
189,525 $12.2 Million
Q4 2020

Feb 11, 2021

BUY
$56.65 - $64.55 $432,636 - $492,968
7,637 Added 4.53%
176,191 $10.3 Million
Q3 2020

Nov 12, 2020

BUY
$62.1 - $78.08 $267,464 - $336,290
4,307 Added 2.62%
168,554 $10.7 Million
Q2 2020

Jul 31, 2020

BUY
$72.34 - $84.0 $246,028 - $285,684
3,401 Added 2.11%
164,247 $12.6 Million
Q1 2020

May 05, 2020

BUY
$62.63 - $80.22 $1.05 Million - $1.35 Million
16,782 Added 11.65%
160,846 $12 Million
Q4 2019

Jan 07, 2020

SELL
$61.62 - $67.78 $252,518 - $277,762
-4,098 Reduced 2.77%
144,064 $9.36 Million
Q3 2019

Oct 23, 2019

BUY
$62.51 - $69.0 $228,974 - $252,747
3,663 Added 2.53%
148,162 $9.39 Million
Q2 2019

Aug 05, 2019

BUY
$61.87 - $69.38 $450,166 - $504,808
7,276 Added 5.3%
144,499 $0
Q1 2019

Apr 26, 2019

BUY
$62.53 - $70.05 $4.23 Million - $4.74 Million
67,686 Added 97.34%
137,223 $0
Q4 2018

Feb 11, 2019

SELL
$60.54 - $79.0 $250,575 - $326,981
-4,139 Reduced 5.62%
69,537 $4.35 Million
Q3 2018

Nov 05, 2018

BUY
$71.28 - $78.92 $3.94 Million - $4.36 Million
55,227 Added 299.35%
73,676 $0
Q3 2018

Nov 05, 2018

SELL
$71.28 - $78.92 $3.9 Million - $4.32 Million
-54,771 Reduced 74.8%
18,449 $0
Q2 2018

Aug 07, 2018

BUY
$64.88 - $75.68 $63,128 - $73,636
973 Added 1.35%
73,220 $0
Q1 2018

May 02, 2018

SELL
$72.84 - $88.8 $38,022 - $46,353
-522 Reduced 0.72%
72,247 $0
Q4 2017

Jan 25, 2018

SELL
$71.15 - $83.52 $186,911 - $219,407
-2,627 Reduced 3.48%
72,769 $0
Q3 2017

Nov 09, 2017

SELL
$72.11 - $85.47 $64,250 - $76,153
-891 Reduced 1.17%
75,396 $0
Q2 2017

Aug 14, 2017

BUY
N/A
76,287
76,287 $0

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.